These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33247497)

  • 1. Infectious complications in allogeneic hematopoietic cell transplant recipients: Review of transplant-related risk factors and current state of prophylaxis.
    Akhmedov M
    Clin Transplant; 2021 Feb; 35(2):e14172. PubMed ID: 33247497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation.
    Törlén J; Ringdén O; Garming-Legert K; Ljungman P; Winiarski J; Remes K; Itälä-Remes M; Remberger M; Mattsson J
    Haematologica; 2016 Nov; 101(11):1417-1425. PubMed ID: 27662016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of graft-versus-host disease with rituximab-containing conditioning regimens in allogeneic hematopoietic stem cell transplant.
    Marini BL; Markstrom D; Frame D
    J Oncol Pharm Pract; 2017 Jun; 23(4):255-263. PubMed ID: 26970572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic hematopoietic stem cell transplant recipients and parasitic diseases: A review of the literature of clinical cases and perspectives to screen and follow-up active and latent chronic infections.
    Fabiani S; Fortunato S; Petrini M; Bruschi F
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28128496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.
    Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for cefepime nonsusceptible Gram-negative infections in allogeneic hematopoietic cell transplant recipients.
    Boyd AM; Perissinotti AJ; Nagel JL; Frame DG; Marini BL
    J Oncol Pharm Pract; 2019 Mar; 25(2):279-288. PubMed ID: 28950805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic stem cell transplant with HLA-mismatched grafts: impact of donor, source, conditioning, and graft versus host disease prophylaxis.
    Metheny L; de Lima M
    Expert Rev Hematol; 2019 Jan; 12(1):47-60. PubMed ID: 30582393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant.
    Ruggeri A; Sun Y; Labopin M; Bacigalupo A; Lorentino F; Arcese W; Santarone S; Gülbas Z; Blaise D; Messina G; Ghavamzadeh A; Malard F; Bruno B; Diez-Martin JL; Koc Y; Ciceri F; Mohty M; Nagler A
    Haematologica; 2017 Feb; 102(2):401-410. PubMed ID: 27758821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burden of cytomegalovirus disease in allogeneic hematopoietic cell transplant recipients: a national, matched cohort study in an inpatient setting.
    Hakimi Z; Ferchichi S; Aballea S; Odeyemi I; Toumi M; English M; Yakoub-Agha I
    Curr Res Transl Med; 2018 Nov; 66(4):95-101. PubMed ID: 30274738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Considerations in Preparative Regimen Selection to Minimize Rejection in Pediatric Hematopoietic Transplantation in Non-Malignant Diseases.
    Hayashi RJ
    Front Immunol; 2020; 11():567423. PubMed ID: 33193340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of infectious complications after allogeneic hematopoietic stem cell transplantation.
    Sahin U; Toprak SK; Atilla PA; Atilla E; Demirer T
    J Infect Chemother; 2016 Aug; 22(8):505-14. PubMed ID: 27344206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation.
    Pasic I; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Mattsson J; Michelis FV
    Ann Hematol; 2020 Jun; 99(6):1377-1387. PubMed ID: 32382774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.
    Kołodziejczak M; Gil L; de la Camara R; Styczyński J;
    Ann Hematol; 2021 Mar; 100(3):763-777. PubMed ID: 33491135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of late complications of allogeneic hematopoietic stem cell transplantations.
    Atilla E; Atilla PA; Toprak SK; Demirer T
    Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28753218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute graft versus host disease in hematopoietic stem cell alotransplant recipients.
    Krstevska S; Genadieva-Stavric S; Pivkova A; Stojanovski Z; Georgievski B; Balkanov T
    Med Arh; 2011; 65(5):260-4. PubMed ID: 22073847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver disease during and after hematopoietic stem cell transplantation in adults: a single-center Egyptian experience.
    Abdelbary H; Magdy R; Moussa M; Abdelmoaty I
    J Egypt Natl Canc Inst; 2020 Feb; 32(1):11. PubMed ID: 32372257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune deficits in allogeneic hematopoietic stem cell transplant (HSCT) recipients.
    Mir MA; Battiwalla M
    Mycopathologia; 2009 Dec; 168(6):271-82. PubMed ID: 19156534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics comparisons of bacteremia in allogeneic and autologous hematopoietic stem cell-transplant recipients with levofloxacin prophylaxis and influence on resistant bacteria emergence.
    Wang CH; Chang FY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
    J Microbiol Immunol Infect; 2018 Feb; 51(1):123-131. PubMed ID: 27103500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.